Sentences with phrase «society of oncology»

Oral Presentation Annual Surgical Society of Oncology Meeting, Seattle, Washington.

Surgical Society of Oncology Meeting, Seattle, Washington.

Once tests and exams come back indicating cancer, says David S. Parda, MD, FACP, past president of the Pennsylvania Society of Oncology & Hematology, it's time for the patient and her physician - led health care team to come up with a plan to fight it.

Not exact matches

Today is the last day of the annual American Society of Clinical Oncology (ASCO) meeting in Chicago.

«The American Society of Clinical Oncology (ASCO) applauds the U.S. Senate for their decisive vote today to pass the 21st Century Cures Act and authorize funding for the Beau Biden Cancer Moonshot and NIH Innovation Projects,» wrote the organization in a statement.

In a statement released Tuesday, the American Society of Clinical Oncology outlined research tying alcohol to two types of cancer and told Americans to drink less.

Johnson & Johnson's cancer treatment Zytiga significantly cut the death risk for newly - diagnosed, advanced prostate cancer patients by 38 %, according to data unveiled at the ongoing American Society of Clinical Oncology (ASCO) annual meeting this weekend.

Now, we're getting the first look at that answer in data presented as part of the American Society of Clinical Oncology annual conference, which starts Friday.

The annual meeting of the American Society of Clinical Oncology (ASCO) wrapped up on Tuesday afternoon.

BIG DATA AND CANCER: STANDARDIZATION With Mary Beckerle of the University of Utah; Clifford A. Hudis of the American Society of Clinical Oncology; Greg Simon of The White House; and Clifton Leaf of Fortune — Report by Erika Fry — Video: The Crucial Data That Will Help You Fight Cancer — Video of the entire session

Dr. Clifford A. Hudis, Chief Executive Officer, American Society of Clinical Oncology Greg Simon, Executive Director, Cancer Moonshot Task Force, The White House Dr. Ken Robert Smith, Distinguished Professor of Family Studies and Population Science; Director, Utah Population Database, University of Utah Moderator: Clifton Leaf, Fortune

Participants included CEOs Jonathan Bush of Athenahealth, Ron Gutman of HealthTap, Dr. Clifford Hudis of the American Society of Clinical Oncology, Dr. Vivian Lee of University of Utah Health Care, VitalConnect CEO Nersi Nazari, James Park of Fitbit, and Andrew Witty of GSK, as well as President of Flex Health Solutions John Carlson, Multiple Myeloma Research Foundation Founder Kathy Giusti, Dr. Sanjay Gupta, Arianna Huffington, Andreessen Horowitz General Partner Vijay Pande, Parker Foundation President Sean Parker, Women's Alzheimer's Movement Founder Maria Shriver, and White House Cancer Moonshot Task Force Executive Director Greg Simon.

The American Society of Clinical Oncology's annual meeting ended Tuesday.

Materials provided by American Society of Clinical Oncology.

«Although FDA approval is critically important for introducing a new screening test or algorithm, providers ultimately rely on guidance or guidelines to help them make the best decisions for their patients and want to understand advantages, disadvantages and unknowns associated with a new screening approach,» said Huh, who is a senior scientist for the UAB Comprehensive Cancer Center, Director of the UAB Division of Gynecologic Oncology, and is also a board member for both the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology.

American Society of Clinical Oncology.

However, its use during concurrent chemo - radiotherapy in SCLC is controversial and the American Society of Clinical Oncology (ASCO) recommends against its routine use.

Results of the trial, reported in the May 31 issue of the New England Journal of Medicine and presented at the American Society for Clinical Oncology 2015 annual meeting, also showed that after a year, the nivolumab group had nearly double the survival rate (42 percent) of the chemotherapy patients (24 percent).

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

The study appears this week in the early online edition of the Journal of Clinical Oncology, a peer - reviewed journal of the American Society of Clinical Oncology.

Physician - scientists at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented their findings and strategies to increase rates on March 13 at the Society of Surgical Oncology Cancer Symposium in Phoenix.

People diagnosed with cancer gained 3.34 million years of life thanks to cancer clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's largest clinical cancer research meeting.

[1] The European Cancer Congress is the 18th congress of the European CanCer Organisation (ECCO) and the 40th congress of the European Society for Medical Oncology (ESMO).

Young people with body mass indexes (BMIs) over 30 are more likely to experience aggressive malignancies, says author Nathan A. Berger, MD, Hanna - Payne Professor of Experimental Medicine; director of the Center for Science, Health and Society; member of the Case Comprehensive Cancer Center; and professor of medicine, biochemistry, oncology and genetics at Case Western Reserve University School of Medicine.

Materials provided by American Society of Clinical Oncology (ASCO).

As reported at the American Society of Clinical Oncology meeting in June, the vaccine, together with radiation and chemotherapy, prevented the brain tumor from reemerging after surgery for 12 months as compared with the typical six to seven months with no vaccine.

American Society of Clinical Oncology (ASCO).

The American Society of Clinical Oncology (ASCO) today announced results from four major studies to be presented at ASCO's 51st Annual Meeting, May 29 - June 2, in Chicago.

The findings will be presented at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago.

An «alarmingly» high level of shortages continue to exist across oncology, according to the American Society of Clinical Ooncology, according to the American Society of Clinical OncologyOncology.

The results were presented during the 2017 Gastrointestinal Cancers Symposium, sponsored by the American Society of Clinical Oncology, in San Francisco.

Society of Gynecologic Oncology.

Results of the work are being presented at the 2017 Genitourinary Cancers Symposium (co-sponsored by the American Society of Clinical Oncology, American Society for Radiation Oncology and the Society of Urologic Oncology) in Orlando later this week.

Materials provided by Society of Gynecologic Oncology.

«There are many ways to access information about clinical trials,» offers Linda Krebs, past president of the Oncology Nursing Society.

«It has to be more of an individualized approach to the type of cancer and even the patient,» says the University of Nebraska, Omaha's Julie Vose, president of the American Society of Clinical Oncology (ASCO).

Connecting a global network of more than 40,000 cancer professionals, the society serves as the leading resource for best practices in clinical oncology research and academic and community practices.

The abstracts are scheduled to be presented at the 2014 annual meeting of the American Society of Clinical Oncology in Chicago May 30 - June 3rd.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

New research presented at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago shows that a previously untested combination of a monoclonal antibody - drug conjugate with a common chemotherapy agent has a high complete - response rate in children and young adults with relapsed or refractory Hodgkin lymphoma.

Additional details will be presented at the American Society of Clinical Oncology annual meeting next month in Chicago.

Hawley will present the findings Nov. 30 at the American Society of Clinical Oncology's Quality Care Symposium.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

«While e-cigarettes may reduce smoking rates and attendant adverse health risks, we will not know for sure until these products are researched and regulated,» said Peter Paul Yu, president of the 35,000 - member American Society of Clinical Oncology, in a statement.

They will present their findings in an oral presentation June 1 at the annual meeting of the American Society of Clinical Oncology in Chicago.

Maria Die Trill, president of the International Psycho - Oncology Society at the Hospital Gregorio Marañón in Madrid, wrote in a testimonial that she expected her PEN interview to help «spread the word» about the sSociety at the Hospital Gregorio Marañón in Madrid, wrote in a testimonial that she expected her PEN interview to help «spread the word» about the societysociety.

A comprehensive analysis of the study's results — published in June 1 online edition of the New England Journal of Medicine and to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago — found participants treated with enzalutamide saw an 81 percent reduction in the risk the cancer would progress and a 29 percent reduction in the risk of death.

Sylvia Adams, MD, associate professor of medical oncology at Perlmutter Cancer Center and principal investigator of this study, presented the findings on June 3 in Chicago at the annual meeting of the American Society of Clinical Ooncology at Perlmutter Cancer Center and principal investigator of this study, presented the findings on June 3 in Chicago at the annual meeting of the American Society of Clinical OncologyOncology.

«It's 11 questions, and it's not hard to do,» says Hurria, who just completed a two - year term as president of the International Society of Geriatric Oncology.

In a preliminary finding (abstract 5568) presented Monday, June 6, at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago, researchers revealed they have found bacteria in the ovaries and in the fallopian tubes.